Five Years of Freedom: CARVYKTI Redefines Hope for Myeloma Warriors
- Unprecedented Survival: A groundbreaking 33% of heavily pretreated multiple myeloma patients remain progression-free five years after a single CARVYKTI® infusion.
- One and Done: Patients achieved this remarkable milestone without any maintenance or subsequent myeloma therapy.
- Paradigm Shift: Data from the CARTITUDE-1 study signals a fundamental change in treatment expectations for relapsed/refractory multiple myeloma (RRMM).
SOMERSET, N.J. – In a stunning announcement at the 2025 ASCO Annual Meeting, Legend Biotech (NASDAQ: LEGN) unveiled five-year survival data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) that is rewriting the future for patients battling relapsed/refractory multiple myeloma. The CARTITUDE-1 study (NCT03548207) showed that an unprecedented one-third (32 of 97) of these heavily pretreated patients remained alive and free of disease progression five years or more after a single infusion of CARVYKTI®, with no further myeloma treatment needed.
These patients, with a median age of 61 and having endured a median of 6.5 prior therapies6, faced daunting prognoses. "The durability and consistency we’re seeing with CARVYKTI® in the CARTITUDE-1 study is truly remarkable,” said Sundar Jagannath, M.D., of The Tisch Cancer Institute. “These data offer real hope for long-term disease control in a population that previously had limited options.”
CARVYKTI® is the first and only CAR T-cell treatment in multiple myeloma to show an overall survival benefit versus standard of care7. In a compelling subset of 12 patients who underwent serial minimal residual disease (MRD) assessments, all remained progression-free and MRD-negative for five years. Safety signals were consistent with CARVYKTI®'s known profile, with no new movement or neurocognitive adverse events reported in this long-term follow-up6.
“This five-year survival data highlights the potential of CARVYKTI® to fundamentally change treatment expectations," stated Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Legend Biotech. "For one-third of these heavily pre-treated patients to remain progression-free for five years after a single infusion...represents a potential paradigm shift."
Further bolstering these findings, data from the CARTITUDE-4 study (NCT04181827) presented at ASCO supports CARVYKTI®'s favorable benefit-risk profile as early as after first relapse for certain high-risk patients3, 4. Legend Biotech also shared promising early data from its pipeline targeting solid tumors, including LB1908 for gastric cancers (NCT04728878) and LB2102 for small-cell lung cancer (NCT05331269).
"Legend is working to leverage cutting-edge cell therapy modalities to create paradigm-shifting treatments and potential cures for cancer patients," affirmed Ying Huang, Ph.D., CEO of Legend Biotech.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.